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Orosomucoid 1-Like Protein 3 (ORMDL3) is an asthma candidate gene and Casitas B lineage lym-
phoma b (Cbl-b), an E3 ubiquitin ligase, is a critical factor in maintaining airway immune tolerance.
However, the association of Cbl-b with ORMDL3 for asthma is unclear. Here, we show that expres-
sion of ORMDL3 is signiﬁcantly increased and shows a strong linear correlation with decreased
Cbl-b in the peripheral blood of recurrent wheeze patients. To elucidate the molecular mechanisms
underlying this correlation, we identiﬁed that Cbl-b suppressed the transcriptional activity and
mRNA expression of ORMDL3 in vivo. Further investigation showed that phosphorylation of signal
transducer and activator of transcription 6 (STAT6) was induced by interleukin 4 bound to the
ORMDL3 promoter, while Cbl-b reduced the phosphorylation of STAT6. Our results show that
Cbl-b suppresses human ORMDL3 expression through STAT6.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction immunity/anergy switchpoint at several levels through interactionsIt is well known that asthma is one of the most common chronic
diseases and genetic variability contributes to asthma risk.
Orosomucoid 1-Like Protein 3 (ORMDL3) was found as a candidate
gene associated with asthma susceptibility by genome-wide asso-
ciation studies in diverse human populations [1–4]. The ORMDL3
protein modiﬁes key steps in the processing of T lymphocyte acti-
vation, providing a functional link between genetic associations
and several autoimmune and inﬂammatory diseases [5]. The study
of ORMDL3 on ER-mediated Ca2+ signaling and facilitation of
ER-mediated inﬂammatory responses increases our understanding
of the association between ORMDL3 and asthma [6,7].
E3ubiquitin-protein ligaseCasitas B lineage lymphomab (Cbl-b),
a ubiquitin ligase controlling tolerance, was proposed to impact thewithdifferent target substrates [8]. Functional studies indicated that
Cbl-b is involved in the regulation of peripheral tolerance, anergy of
T cells, and B cell antigen receptor signaling [9,10]. Additionally,
Cbl-b deﬁciency leads to a breakdown of tolerance to an allergen,
ovalbumin, severe airway inﬂammation, and stronger responses
by T helper cells type 2 (Th2) and 9 (Th9) [11,12].
Despite the important roles of ORMDL3 and Cbl-b in asthma, few
studies have investigated the function of Cbl-b in the regulation of
human ORMDL3. In this study, we tested the hypothesis that Cbl-b
is essential in regulating ORMDL3 expression. Furthermore, we
found that signal transducer and activator of transcription 6
(STAT6) mediates Cbl-b-induced ORMDL3 downregulation. These
results may provide a target for therapeutic intervention aimed at
altering ORMDL3 expression level by Cbl-b in patients with asthma.
2. Materials and methods
2.1. Patient recruitment and sample collection
We recruited unrelated Chinese children of Han ethnicity, 11
with recurrent wheeze and 13 unaffected controls, who underwent
1976 W.-X. Yang et al. / FEBS Letters 589 (2015) 1975–1980comprehensive medical screening from the First Afﬁliated Hospital
of Nanjing Medical University of China. Blood samples were
obtained from subjects and controls after their informed consent
was obtained (Table 1). ‘‘Recurrent wheeze’’ was deﬁned as two
or more physician-veriﬁed episodes of wheezing during a 1-year
follow-up [13]. The deﬁnition here was at least four episodes
before study entry were enrolled. Normal controls were children
without respiratory complaints and with no history of wheeze or
any allergies at the time of recruitment. All cases and
non-allergic controls were free from infectious symptoms for
4 weeks before the study [14]. Recruitment and blood collection
were approved by the Clinical Research Ethics Committee of the
First Afﬁliated Hospital of Nanjing Medical University.
2.2. Cell culture and chemicals
Human type II alveolar lung epithelium cells (A549), epithelial
carcinoma cells (HeLa), Jurkat T cells, and embryonic kidney cells
transformed with large T antigen (293T) obtained from the
American Type Culture Collection (ATCC) were cultured in
Dulbecco’s Modiﬁed Eagle Medium (Hyclone, USA) or RPMI-1640
medium (Gibco/Invitrogen) with 10% heat inactivated fetal bovine
serum, supplemented with penicillin (100 U/mL) and streptomycin
(100 mg/mL; Gibco BRL, Gaithersburg, MD, USA). Cells were incu-
bated at 37 C and equilibrated with 5% CO2 by standard cell cul-
ture techniques. Interleukin 4 (IL-4) was obtained from
Peprotech (Rocky Hill, NJ, USA).
2.3. Plasmids and small interfering RNA (siRNA)
A reporter plasmid, pGL84/+58, containing short fragments of
the ORMDL3 promoter was constructed as previously described
[14]. For overexpression studies, the Cbl-b expression plasmid
pEGFP-Cbl-b and the pEGFP-basic vector were provided by
Genechem. Double-stranded siRNAs were synthesized and
high-performance puriﬁed (GenePharma). The siRNA target
sequences used to silence the transcription of speciﬁc genes were
as follows:
Cbl-b: 1) 50-GCCUGAUACAUAUCAGCAUTT-30 (sense), 50-AUGC
UGAUAUGUAUCAGGCTT-30 (antisense);
Cbl-b: 2) 50-GCGGAAUUGGAAUUUCUUATT-30 (sense), 50-UAAG
AAAUUCCAAUUCCGCTT-30 (antisense);
Cbl-b: 3) 50-GCAUGCCGAUGCUAGACUUTT-30 (sense), 50-AAGU
CUAGCAUCGGCAUGCTT-30 (antisense);
Control: 50-UUCUCCGAACGUGUCACGU-30 (sense), 50-ACGUGA
CACGUUCGGAGAATT-30 (antisense).
2.4. Transient transfections and luciferase assays
Transient transfections were carried out in 293T and A549 cells
using Lipofectamine™2000 (Invitrogen) according to the manufac-
turer’s instructions. Cells were seeded into 96-well plates (15000
cells per well) and cultured overnight. To investigate Cbl-b siRNA
dose-dependence, 100 ng of the promoter reporter plasmid and
4 ng pRL-TK plasmid (Promega) plus 0–15 pmol siRNA for Cbl-bTable 1
Clinical characteristics of subject.
Controls (n = 13) Wheeze (n = 11)
Age (months) 25.23 ± 8.73 21.64 ± 8.25
Gender (male/female) 6:7 4:7
Eczema history (male/female) 0:0 6:5
Allergy history (male/female) 0:0 7:4
Data are presented as the mean ± S.D.were co-transfected into cells and harvested after 24 h. To study
Cbl-b overexpression response, 100 ng luciferase reporter plasmid
and 4 ng PRL-TK plasmid with Cbl-b expression plasmid were
co-transfected into cells for 24 h before luciferase assays were car-
ried out. For both Cbl-b siRNA and overexpression, cells were incu-
bated with IL-4 for 30 m before luciferase assays. Luciferase
activity was measured using the Dual Reporter Assay System
(Promega) and TD-20/20 Turner Designs Luminometer. Results
are representative of at least three independent experiments.2.5. Quantitative RT-PCR
Total RNA was extracted from human leukocytes or cultured
cells using TRIzol Reagent (Invitrogen), and subsequently
reverse-transcribed into ﬁrst strand cDNA using the Prime Script
RT Master Mix Perfect Real Time Kit (Takara). Quantitative
real-time PCR (qRT-PCR) was performed on the Applied
Bio-systems Step One Plus Real-Time PCR System (SYBR Green;
Takara). Expression of the gene of interest was normalized to
human GAPDH (Santa Cruz Biotechnology) and relative expression
level was calculated with the comparative Ct method. The primer
sequences were as following: 50-TCCATGGAGTTGGTCATGGAA-30
(sense), 50-GCCTGAGGGCAAACAAGTGAG-30 (antisense) for
ORMDL3;
50-AATCCCCGAAAAGGTCGAATTT-30 (sense), 50-CACAGTCTTACC
ACTTTGTCCAT-30 (antisense) for Cbl-b;
50-GGAGCGAGATCCCTCCAAAAT-30 (sense), 50-GGCTGTTGTCAT
ACTTCTCATGG-30 (antisense) for GAPDH.
2.6. Western blot analysis
Cell cultures in 60 mm dishes were scraped into lysis buffer at
various time points and were extracted using the Total Protein
Extraction Kit (Keygentec, China). Protein concentrations were
determined using the Bio-Rad Protein Assay (Bio-Rad). A total of
30–40 lg of protein was extracted by 10% sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis and then transferred to a
nitrocellulose membrane. The blots were blocked in Tris–buffered
saline-0.1% Tween-20 containing 5% non-fat milk and then incu-
bated with antibodies at 4 C overnight. Primary antibodies for
p-Stat6 (Abcam), Cbl-b (C-20: sc-1435, Santa Cruz Biotechnology),
ORMDL3 (Abcam) and GAPDH were used at dilutions of 1:1000,
1:1000, and 1:2500, respectively. The secondary antibody was
anti-mouse or anti-rabbit IgG (Santa Cruz Biotechnology) and
was used at a 1:2000 dilution for 1 h at room temperature.
Chemoluminescence signals were quantiﬁed using an ECL imager,
and analyzed using Quantity One software (Bio-Rad).
2.7. Chromatin immunoprecipitation (ChIP) assay
ChIP was performed with the ChIP-IT kit (Active Motif) follow-
ing the manufacturer’s instructions. 293T cells were grown to 95%
conﬂuence and ﬁxed in 1% formaldehyde at room temperature for
15 m. Isolated nuclei were lysed with lysis buffer followed by chro-
matin shearing with the Enzymatic Shearing kit (Active Motif). The
chromatin was then immunoprecipitated with 2 lg anti-IgG anti-
body (Active Motif) and anti-STAT6 antibody (Abcam). A DNA sam-
ple from sonicated nuclear lysates that underwent reverse
cross-linking and phenol/chloroform extraction was used as a pos-
itive control (input). A DNA sample immunoprecipitated with anti-
bodies against IgG was used as a negative control. DNA from input
(1:10 diluted) or immunoprecipitated samples was assayed by
PCR. The promoter-speciﬁc primers were: sense: 50-AACCGTGCGT
CCCCGAAGA-30; antisense: 50-GCAGCTCCGGCCGAATCA-30.
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Statistical analysis was performed using SPSS Software (version
16). The results were analyzed using paired or unpaired t-tests.
Correlation was tested with a Pearson correlation test. Data were
representative of at least three independent experiments, and
P < 0.05 was considered signiﬁcant.3. Results
3.1. Expression and association of Cbl-b and ORMDL3 in recurrent
wheeze and normal subjects
We analyzed the levels of Cbl-b and ORMDL3 in peripheral blood
leukocytes from normal subjects and recurrent wheeze patients by
qRT-PCR. We observed decreased expression of Cbl-b in wheeze
patients compared with controls (Fig. 1A; mean ± S.D.
0.1029 ± 0.06454 vs. 0.0562 ± 0.03294, P < 0.05), while ORMDL3
expression was signiﬁcantly increased in recurrent wheeze
patients (Fig. 1B; mean ± S.D. 0.0148 ± 0.01063 vs. 0.0367 ±
0.01061; P < 0.001). Cbl-b expression showed a strong linear corre-
lation with the expression of ORMDL3 in recurrent wheeze patients
and normal subjects (Fig. 1C: r = 0.8127, P < 0.01).Fig. 1. Expression and association of Cbl-b and ORMDL3 in recurrent wheeze (n = 11) an
real-time qRT-PCR. (A and B) The differences of expression levels for Cbl-b and ORMDL
unpaired t-test: ***P < 0.001,*P < 0.05. (C) The correlation between ORMDL3 and Cbl-b wa
Fig. 2. Cbl-b decreases ORMDL3 promoter activity. (A and B) A549 and 293-T cells were
minimal promoter and different dose Cbl-b siRNA (0–15 pmol) or Cbl-b expression plasmi
4 (30 ng/mL) for 30 m before luciferase activity detecting. Relative luciferase activity o
siRNA or PEGFP-basic was set as 1.0 (**P < 0.01). The mean values (S.D.) of three indepen
dose siRNA of Cbl-b or Cbl-b expression plasmid. After 48 h, Cbl-b proteins were detect3.2. Cbl-b decreases ORMDL3 promoter activity
To conﬁrm the role of Cbl-b in the regulation of ORMDL3 pro-
moter activity, we cotransfected plasmids pGL84/+58 and
pGL-TK, together with the Cbl-b expression plasmid (0–100 ng)
or Cbl-b siRNA (0–15 pmol), into A549 and 293T cells. Repression
of endogenous expression of Cbl-b induced a dose-dependent
increase in the promoter activity of ORMDL3, especially with
15 pmol Cbl-b siRNA (1.28–2.12–fold for A549, 1.27–2.49-fold for
293T; Fig. 2A). Meanwhile, overexpression of Cbl-b decreased
transcriptional activity of the ORMDL3 promoter (23–80% for
A549, 25–89% for 293T; Fig. 2B), indicating that Cbl-b mediated
transcriptional activity of the ORMDL3 promoter. Expression of
Cbl-b by the introduction of siRNA or expression plasmids was
conﬁrmed by Western blot analysis (Fig. 2C and D).
3.3. Cbl-b negatively regulates ORMDL3 mRNA expression
To further examine whether Cbl-b affects the endogenous
expression of ORMDL3, we analyzed the mRNA levels of ORMDL3
in Hela and 293T cells by qRT-PCR. Because IL-4 upregulates
ORMDL3 expression [15], we explored whether Cbl-b participates
in regulating ORMDL3 expression induced by IL-4. Endogenous
ORMDL3 expression was upregulated in IL-4-treated 293T cells atd normal subjects (n = 13). The expression of ORMDL3 and Cbl-b were analyzed by
3 between recurrent wheeze patients and normal subjects were detected using an
s tested with a Pearson correlation test (**P < 0.01).
cotransfected with the luciferase reporter plasmid containing the ORMDL3 proximal
d (0–100 ng). For both Cbl-b siRNA and overexpression, cells were incubated with IL-
f the ORMDL3 promoter controlled by reporter plasmid cotransfected with control
dent experiments are shown. (C and D) A549 cells were transfected with different
ed by Western blot analysis.
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icant at a concentration of 30 ng/mL than for the control and other
groups (Fig. 3B). siRNA knockdown of Cbl-b enhanced ORMDL3
mRNA expression by IL-4 (Fig. 3D), whereas overexpression of
Cbl-b reduced ORMDL3mRNA expression and eliminated the effect
of IL-4 on endogenous ORMDL3 mRNA expression (Fig. 3C). These
data demonstrate that Cbl-b regulates expression of endogenous
ORMDL3.
3.4. STAT6 mediates Cbl-b-induced ORMDL3 downregulation
IL-4 upregulation of ORMDL3 expression depends on STAT6
phosphorylation in vivo [7]. Thus, we investigated whether Cbl-b
reduced ORMDL3 expression by STAT6. We transfected Cbl-b
expression plasmids or Cbl-b siRNA into 293T cells and incubated
for 24 h, then further incubated for 30 m in the presence of IL-4.
siRNA knockdown of Cbl-b enhanced the phosphorylation of
STAT6, while overexpression of Cbl-b eliminated the effect of IL-4
on phosphorylation of STAT6, suggesting that Cbl-b might play
an important role in the regulation of degradation of phosphory-
lated STAT6 (Fig. 4A and B). To investigate whether STAT6 binds
to the ORMDL3 promoter in vivo, we performed a ChIP assay using
293T cells. As shown in Fig. 4C, STAT6 antibodies, but not IgG anti-
bodies, immunoprecipitated the ORMDL3 promoter. This demon-
strated the binding of STAT6 transcription factors to the
endogenous ORMDL3 promoter. To further identiﬁed this signaling
pathway in T cells, we transfected Cbl-b siRNA or pEGFP-Cblb into
Jurkat cells and cultured for 24 h. Western blot were performed for
the protein levels of ORMDL3 after IL-4 treatment for 30 m. The
knockdown or overexpression of Cbl-b signiﬁcantly change the
protein expression of the ORMDL3 gene (Fig. 4D).4. Discussion
ORMDL3 is the ER-based protein coded by the ORMDL3 gene,
located on chromosome 17q12, which is associated withFig. 3. Cbl-b negatively regulates ORMDL3mRNA expression. (A) Effect of IL-4 treatment
(B) IL-4 induced ORMDL3 expression for 24 h in a dose-dependent manner in 293-T cell. (
pEGFP-Cblb mediated over expression of Cbl-b (*P < 0.05, **P < 0.01, 4P < 0.05). The meansusceptibility to several inﬂammatory and autoimmune diseases
such as asthma and type 1 diabetes [16,17]. One mechanism
involved in the pathophysiology of these diseases is the modiﬁca-
tion of T cell calcium signaling and lymphocyte activation by
ORMDL3 following alteration of the mitochondria [5,6]. Our group
previously showed that ORMDL3 expression is cooperatively regu-
lated by the transcription factors Ets-1, p300 and CREB [14,18–20].
Other studies have demonstrated that the IL-4/STAT6 signaling
pathway also plays a vital role in inducing mouse and human
ORMDL3 expression [15,21,22].
Peripheral T cell tolerance is an important component of a
healthy immune response to inhaled antigens. Cbl-b is a key mole-
cule in the induction of tolerance and in the maintenance of
immunological homeostasis in the airway [23]. Studies have estab-
lished a direct functional link between Cbl-b and airway immune
responses based on several possible mechanisms; Cbl-b-deﬁcient
T cells are less sensitive to regulatory T cell-mediated suppression
and fail to develop T cell anergy [11]. Cbl-b not only regulates T cell
anergy induction, but is also critical for maintaining Foxp3 expres-
sion (for example, Cbl-b facilitates Foxp3 expression by suppress-
ing Akt-2, but targets Foxp3 for ubiquitination once Foxp3 is
expressed). Thus Cbl-b regulates peripheral T cell tolerance via
multiple mechanisms [24,25].
To determine the association between ORMDL3 and Cbl-b, we
examined their expression proﬁles and showed that ORMDL3
expression was signiﬁcantly increased in the peripheral blood of
recurrent wheeze patients compared with normal control subjects.
However, the relative expression level of Cbl-bwas diminished and
showed a strong linear correlation with the expression of ORMDL3.
Little is known about the reasons for this correlation. We
addressed this question and found that the repression of endoge-
nous Cbl-b expression increased the promoter activity, mRNA and
protein expression of the ORMDL3 gene, while overexpression of
Cbl-b reduced ORMDL3 expression. These observations suggest that
Cbl-b is a negative regulator for ORMDL3.
STAT6 is an asthma candidate gene that is essential for
IL-4-mediated immunoglobulin class switching to IgE [26].of optimized concentration for 12 h or 24 h on the ORMDL3mRNA level in 293-T cell.
C and D) Quantiﬁcation of ORMDL3mRNA level after siRNA mediated knockdown or
values (S.D.) of three independent experiments are shown.
Fig. 4. STAT6 mediates Cbl-b-induced ORMDL3 down-regulation. (A and B) 293-T cells were transfected with Cbl-b siRNA or pEGFP-Cblb and incubated for 24 h, then further
incubated in the presence of IL-4 (30 ng/mL). After 30 m, P-STAT6, STAT6 and GAPDH protein expression were analyzed by Western blot. (C) ChIP assays to test the binding of
STAT6 to the promoter of ORMDL3 in vivo. Anti-RNA Pol II (positive control antibody) and anti-STAT6 bodies precipitated proteins bound to the ampliﬁed sequence of the
endogenous ORMDL3 promoter whereas non-speciﬁc IgG (negative control antibody) failed to precipitate proteins bound to this sequence. PCR products were visualized by
agarose gel electrophoresis and ethidium bromide staining. (D) Jurkat T cells were transfected with Cbl-b siRNA or pEGFP-Cblb and cultured for 24 h, then Western blot were
performed for the protein levels of ORMDL3 after IL-4 (30 ng/mL) treatment for 30 m. Immunoblots are representative of three independent experiments; ChIP assays show
one out of three independent experiments.
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most airway hyperresponsiveness in mouse models [27].
Moreover, STAT6 was predominantly required for the activation
of transcription leading to the Th2 cell phenotype and repressing
the expression of T-bet and Foxp3 in Th9 cells [28–30]. Recently,
STAT6 was found to be signiﬁcantly associated with recurrent
wheezing in early childhood and participates in regulating
ORMDL3 transcriptional activity [15,21]. We performed ChIP
experiments in 293T cells and showed that under induction by
IL-4, STAT6 regulates ORMDL3 expression by binding to the
ORMDL3 promoter region. The phosphorylation of STAT6 is a criti-
cal step for its catalytic activity [31]. STAT6 ubiquitination is a crit-
ical posttranslational regulatory mechanism for STAT6. Guilin Qiao
et al. found Cbl-b as a key E3 ubiquitin ligase selectively associates
with STAT6 upon IL-4 ligation and targets STAT6 for ubiquitination
and degradation. STAT6 phosphorylation at Y641 is required for its
ubiquitination and degradation, lysines 108 and 398 are the ubiq-
uitination sites of STAT6 [12]. Our data showed that overexpres-
sion of Cbl-b resulted in a decrease in STAT6 phosphorylation
induced by IL-4, which revealed that Cbl-b plays an important role
in the regulation of degradation of phosphorylated STAT6.
Surprisingly, although we observed a signiﬁcant decrease in phos-
phorylated STAT6 in the overexpression of Cbl-b (Fig. 4), the knock-
down or overexpression of Cbl-b did not signiﬁcantly change the
amount of STAT6. Cbl-b-STAT6 interaction and STAT6 degradation
requires the signaling through IL-4, which is strengthened by
TCR/CD28 stimulation [12]. 293T cells used in our study lack
TCR/CD28 but retain IL-4R signaling components necessary for
STAT6 activation. This might explain why the amount of STAT6
was not changed signiﬁcantly.
In conclusion, this study shows that the expression of ORMDL3
is signiﬁcantly upregulated, while Cbl-b expression is downregu-
lated, in patients with recurrent wheeze compared with normal
subjects. Furthermore, expression of ORMDL3 is regulated byCbl-b, which targets STAT6. Understanding this regulatory mecha-
nism is of great importance for the development of new therapeu-
tic strategies for allergic disease, including asthma.
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